Favipiravir vs Hydroxychloroquine vs Control in COVID -19

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

August 11, 2020

Primary Completion Date

March 6, 2021

Study Completion Date

April 7, 2021

Conditions
SARS-CoV 2COVID-19
Interventions
DRUG

Hydroxychloroquine

"400mg BID PO day 1 then 200mg BID PO from day 2 to day 10.~In addition to Hydroxychloroquine all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge."

DRUG

Favipiravir

"1600mg BID PO day 1600mg BID PO day 2 to day 10.~In addition to Favipiravir all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge."

OTHER

Routine care for COVID-19 patients

Supportive care according to local guidelines

Trial Locations (1)

Unknown

Royal College of Surgeons in Ireland - Bahrain, Manama

All Listed Sponsors
collaborator

Ebrahim Khalil Kanoo Community Medical Center

UNKNOWN

collaborator

Hereditary blood Disorder Centre - Salmaniya Medical Complex

UNKNOWN

collaborator

Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, Awali

UNKNOWN

collaborator

Jidhafs COVID-19 Centre

UNKNOWN

collaborator

Sitra FICU

UNKNOWN

collaborator

Salmaniya Medical Complex- 6th Floor

UNKNOWN

collaborator

Salmaniya Medical Complex- Helipad

UNKNOWN

lead

Royal College of Surgeons in Ireland - Medical University of Bahrain

OTHER

NCT04387760 - Favipiravir vs Hydroxychloroquine vs Control in COVID -19 | Biotech Hunter | Biotech Hunter